Now showing items 1-3 of 3

    • Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson’s disease 

      Petzer, Jacobus P.; Petzer, Anél (Bentham Science, 2015)
      The current pharmacological therapies for the treatment of Parkinson’s disease are mostly inadequate and recent, improved therapeutic agents are required. Two important molecular targets for the design of anti-parkinsonian ...
    • Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B 

      Van der Walt, Mietha M.; Terre'Blanche, Gisella; Petzer, Anél; Petzer, Jacobus P.; Van der Walt, Mietha M.; Terre'Blanche, Gisella; Petzer, Anél; Petzer, Jacobus P. (Elsevier, 2012)
      Monoamine oxidase (MAO) plays an essential role in the catabolism of neurotransmitter amines. The two isoforms of this enzyme, MAO-A and -B, are considered to be drug targets for the therapy of depression and neurodegenerative ...
    • α-Tetralone derivatives as inhibitors of monoamine oxidase 

      Legoabe, Lesetja J.; Petzer, Anél; Petzer, Jacobus P. (Elsevier, 2014)
      In the present study, a series of fifteen a-tetralone (3,4-dihydro-2H-naphthalen-1-one) derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. The a-tetralone ...